Want to see AVTX full AI Analyst Report?
Avalo Therapeutics (AVTX) Stock Statistics & Valuation Metrics
Total Valuation
Avalo Therapeutics has a market cap or net worth of $400.71M. The enterprise value is $453.05M.
- Market Cap
- $400.71M
- Enterprise Value
- $453.05M
Share Statistics
Avalo Therapeutics has 57,823,082 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 57,823,082
- Owned by Insiders
- 0.65%
- Owned by Institutions
- 32.31%
Financial Efficiency
Avalo Therapeutics’s return on equity (ROE) is -0.94 and return on invested capital (ROIC) is -70.18%.
- Return on Equity (ROE)
- -0.94
- Return on Assets (ROA)
- -0.67
- Return on Invested Capital (ROIC)
- -70.18%
- Return on Capital Employed (ROCE)
- -0.70
- Revenue Per Employee
- 1,787.879
- Profits Per Employee
- -2.37M
- Employee Count
- 33
- Asset Turnover
- 0.00
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Avalo Therapeutics is -2.52. Avalo Therapeutics’s PEG ratio is 0.01.
- PE Ratio
- -2.52
- PS Ratio
- 6608.31
- PB Ratio
- 0.92
- Price to FCF
- -6.33
- Price to Operating Cash Flow
- -6.50
- PEG Ratio
- 0.01
Income Statement
In the last 12 months, Avalo Therapeutics had revenue of 59.00K and earned -78.26M in profits. Earnings per share was -5.84.
- Revenue
- 59.00K
- Gross Profit
- 59.00K
- Operating Income
- -72.92M
- Pretax Income
- -78.09M
- Net Income
- -78.26M
- EBITDA
- -77.75M
- Earnings Per Share (EPS)
- -5.84
Cash Flow
In the last 12 months, operating cash flow was -61.55M and capital expenditures 0, giving a free cash flow of -61.55M billion.
- Operating Cash Flow
- -61.55M
- Free Cash Flow
- -61.55M
- Free Cash Flow per Share
- -1.12
Dividends & Yields
Avalo Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -15.80%
- Earnings Yield
- -22.16%
Stock Price Statistics
- Beta
- 1.41
- 52-Week Price Change
- -55.06%
- 50-Day Moving Average
- 13.47
- 200-Day Moving Average
- 15.86
- Relative Strength Index (RSI)
- 25.31
- Average Volume (3m)
- 1.58M
Important Dates
Avalo Therapeutics upcoming earnings date is Mar 31, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 05, 2026
- Next Earnings Date
- Mar 31, 2027
- Ex-Dividend Date
- ―
Financial Position
Avalo Therapeutics as a current ratio of 8.14, with Debt / Equity ratio of 2.92%
- Current Ratio
- 8.14
- Quick Ratio
- 8.14
- Debt to Market Cap
- 0.01
- Net Debt to EBITDA
- 0.17
- Interest Coverage Ratio
- 0.00
Taxes
In the past 12 months, Avalo Therapeutics has paid 165.00K in taxes.
- Income Tax
- 165.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Avalo Therapeutics EV to EBITDA ratio is -3.50, with an EV/FCF ratio of -5.28.
- EV to Sales
- 5504.86
- EV to EBITDA
- -3.50
- EV to Free Cash Flow
- -5.28
- EV to Operating Cash Flow
- -5.28
Balance Sheet
Avalo Therapeutics has $392.97M in cash and marketable securities with $153.00K in debt, giving a net cash position of $392.81M billion.
- Cash & Marketable Securities
- $392.97M
- Total Debt
- $153.00K
- Net Cash
- $392.81M
- Net Cash Per Share
- $6.79
- Tangible Book Value Per Share
- $7.74
Margins
Gross margin is 71.19%, with operating margin of -161961.02%, and net profit margin of -150259.32%.
- Gross Margin
- 71.19%
- Operating Margin
- -161961.02%
- Pretax Margin
- -149976.27%
- Net Profit Margin
- -150259.32%
- EBITDA Margin
- -157449.15%
- EBIT Margin
- -117877.97%
Analyst Forecast
The average price target for Avalo Therapeutics is $26.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
- Price Target
- $26.00
- Price Target Upside
- 275.18% Upside
- Analyst Consensus
- Moderate Buy
- Analyst Count
- 7
- Revenue Growth Forecast
- -69.27%
- EPS Growth Forecast
- 66.84%
Scores
- Smart Score
- 4
- AI Score
- 42
